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Abstract: Fibromyalgia (FM) is a chronic widespread pain condition that is estimated to affect 
5 million US adults. Several molecular pathophysiologies are thought to contribute to the 
symptoms of FM, complicating the development of effective clinical management techniques. 
It is now known that abnormalities in both nociceptive and central pain processing systems are 
necessary (but perhaps not sufficient) to condition the onset and maintenance of FM,   producing 
associated neuropsychologic symptoms such as pronounced fatigue, sleep abnormalities, 
  cognitive difficulties, stress sensitivity, anxiety, and depression. Current treatment strategies 
are focused primarily on correcting the pathophysiologic mechanisms underlying these ner-
vous system abnormalities. Clinical studies demonstrate the safety and efficacy of three drugs 
recently approved for the treatment of FM: pregabalin (an alpha-2-delta ligand), and duloxetine 
and milnacipran (serotonin/norepinephrine reuptake inhibitors). This review describes these 
pharmaceuticals in detail and discusses their current roles in FM management.
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Introduction
Fibromyalgia (FM) is a complex chronic pain condition that is defined by widespread 
pain for more than 3 months and the presence of at least 11 of 18 tender points.1 Addi-
tional neuropsychologic symptoms are often present, including pronounced fatigue, 
sleep abnormalities, cognitive difficulties, stress sensitivity, anxiety, and depression.2 
These symptoms are often worsened by physical or emotional stress, cold and humid 
weather, poor sleep, hormonal fluctuations, and lack of exercise,   suggesting a complex 
etiology.3 The prevalence of FM is estimated to be 2% in the US and Canada,4 affecting 
women (3.4%) more frequently than men (0.5%).5 Although children can be diagnosed 
with FM, the median age of onset is 29–37 years,6 with an age-associated increase in 
prevalence.5 Over the past 20 years, FM has emerged as a leading cause of visits to 
rheumatologists, either alone or in conjunction with other rheumatic disorders.7 The 
condition is estimated to affect 5 million US adults,8 and some authors have suggested 
that its prevalence is on the rise.9 However, whether this observation reflects an actual 
increase in prevalence or simply an increased awareness of FM among physicians and 
the general public remains to be investigated.
It is now known that systemic nociceptive and central pain processing abnormalities 
are necessary (although perhaps not sufficient) to condition the onset and maintenance 
of FM. Recent studies suggest that prolonged exposure to a high-stress environment 
combined with polymorphisms in genes involved in stress, anxiety, and pain response 
systems10 may play a significant role in the development of chronic FM pain through Journal of Pain Research 2010:3 90
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physical and functional modifications of the central nervous 
system (CNS), often referred to as “central sensitization”.11 
The following etiologies have also been proposed and, when 
taken collectively, can explain the variable symptomatology 
associated with the condition: autonomic nervous system 
dysfunction, hypothalamic-pituitary-adrenal (HPA) axis 
dysfunction, neurotransmitter abnormalities, an inability 
to sustain deep (Stage 4) sleep, and peripheral   sensitization 
due to microcirculation abnormalities or the release of 
  proinflammatory cytokines from glial cells.3,12
Depression, mood and anxiety disorders, and other 
  psychiatric comorbidities are also considered possible 
  etiologies of FM. These conditions are historically   considered 
to be separate illnesses with high   comorbidity, and the   inability 
to distinguish pre-existing conditions from   manifestations of 
chronic illness has complicated the   identification of cause-
effect relationships. Recent research suggests that these 
conditions are in fact differential symptom presentations of a 
single underlying condition, and that major depressive disorder 
(MDD) and FM (as well as   neuropathic pain) are both associ-
ated with neuroplastic changes in the CNS.13 However, in a 
recent review of the   relationship between FM and MDD, Pae 
et al assert that currently   available findings do not support the 
assumption that MDD and FM refer to the same underlying 
construct, nor can they be seen as subsidiaries of one disease 
concept.14
Regardless of the underlying pathophysiology,   symptoms 
or disorders commonly observed in FM patients, such as 
fatigue, stiffness, cognitive impairment, sleep   disturbances, 
depression, and mood or anxiety   disorders, must be   adequately 
addressed.15 A wide variety of   treatment options are 
  currently available for FM, including pharmacologic agents, 
herbal and dietary supplements, cognitive-behavioral 
therapy,   acupuncture, tender (trigger) point injections, and 
  chiropractic spinal manipulation.16 While new holistic and 
non-pharmacologic approaches are continuously being 
assessed for their efficacy in the treatment of FM, their 
detailed description and assessment are beyond the scope 
of this review (readers are referred to a recent article by 
Hassett and Gevirtz17 for a review of non-pharmacologic 
treatments for FM). Instead, the focus of this article is on 
new   pharmacologic approaches to FM treatment.
The number of randomized controlled trials for FM 
  treatment modalities has risen steadily over the past decade,4 
with pharmaceutical studies focusing on   compounds that 
target the nervous system abnormalities implicated in the 
condition. Such compounds include tricyclic   antidepressants 
(TCAs), selective serotonin reuptake   inhibitors (SSRIs), 
  muscle relaxants, and analgesic medications (eg, non-steroidal 
anti-inflammatory drugs [NSAIDs] and opioids). These 
drugs have a broad range of activities in the brain and 
spinal cord, including modulation of pain sensation and 
tolerance.16 FM patients display a common intolerance to 
many classes of pharmaceuticals, however. This sensitivity 
is likely   conditioned by the same central   sensitivity that is 
presumed to underlie the heightened response to pain seen 
in these patients, limiting the use of therapeutic drugs in FM 
treatment.18
Despite the general intolerance of FM patients to 
  pharmacotherapy, pharmaceuticals remain a cornerstone 
of FM management. Most of the currently employed 
agents are used off-label, with some (eg, TCAs, SSRIs, 
muscle   relaxants) demonstrating greater efficacy than 
others (eg, NSAIDs, opioids).2,16 Specifically, there is no 
evidence that NSAIDs are effective when used alone to 
treat FM. There is, however, limited evidence that suggests 
patients may experience enhanced analgesia when NSAIDs 
are   administered with other agents.19 There have been no 
randomized, clinical trials of opioids in FM, but anecdotal 
evidence suggests that they are not effective. Because their 
use remains controversial, it is suggested that the focus of 
treatment with these drugs should be return to function rather 
than complete elimination of pain.2
The complex, often overlapping, etiologies   responsible for 
FM have produced a patient population with   heterogeneous 
pathology and, to some extent, a heterogeneous   clinical 
  presentation. As a result, FM continues to remain   inadequately 
treated despite the availability of numerous pharmacologic 
and non-pharmacologic treatment approaches. Recent 
advances in our understanding of the   factors   contributing 
to the development and maintenance of FM have identified 
new therapeutic targets,   however. Originally   developed 
as an anticonvulsant medication, pregabalin (Lyrica®) 
became the first FDA-approved drug for the   treatment of 
FM in June 2007. This adjuvant analgesic exerts its thera-
peutic effects by binding to, and decreasing the activity of, 
the alpha-2-delta subunit of the voltage-gated calcium 
ion channel (VGCC).20 VGCC activity is known to play 
an integral role in   nociceptive transmission,   particularly 
in the development and maintenance of nociceptive 
  hypersensitivity, suggesting a mechanism of action for the 
drug’s efficacy in FM.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) are 
a class of antidepressants that have also proven particularly 
efficacious for FM treatment. Unlike SSRIs, which act more 
selectively on the neurotransmitter serotonin (5-HT), SNRIs Journal of Pain Research 2010:3 91
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target and increase the levels of both 5-HT and   norepinephrine 
(NE). The roles of these neurotransmitters in sleep, 
  attention, cognition, anxiety, and, perhaps most   importantly, 
  descending pain inhibition, are thought to facilitate the 
improvement of FM symptoms with SNRI   treatment.21 The 
SNRIs duloxetine (Cymbalta®) and   milnacipran (Savella®) 
were approved by the FDA for the treatment of FM in June 
2008 and January 2009, respectively.
Table 1 provides a summary of standard, new, and 
  emerging FM treatment options. At the time of writing, 
  pregabalin, duloxetine, and milnacipran are the only drugs 
currently approved by the FDA for the clinical treatment of 
FM. This review describes these pharmaceuticals in detail and 
discusses their roles in FM management. While   knowledge of 
standard and emerging therapies is critical for the   optimization 
of individual treatment strategies, a discussion of these 




Pregabalin has exhibited anxiolytic, anticonvulsant, 
and   antinociceptive properties in human and animal 
studies.24 Despite its structural similarity to GABA 
(gamma-aminobutyric acid), pregabalin is devoid of effects 
on GABAA, GABAB, and benzodiazepine   receptors. It also 
has no effect on GABA uptake, degradation, or cerebral 
  concentrations.25 It is currently thought that   pregabalin’s 
effects are instead mediated by its affinity for the 
alpha-2-delta-1 subunit protein of VGCCs. This presynaptic 
binding results in a decrease in excitatory   neurotransmitter 
release of neurochemicals such as substance P, calcitonin 
gene-related peptide, and glutamate.26 These biomolecules 
have been found at pathologically high levels in FM 
patients,11,27 suggesting that pregabalin’s affinity for the 
alpha-2-delta-1 subunit of VGCCs is responsible for its 
therapeutic effects in FM.
Pregabalin is well absorbed after oral administration, 
primarily in the proximal colon.28 The rate of absorption 
is decreased when administered with a meal, resulting 
in an approximately 25%–30% decrease in peak serum 
  concentration (Cmax) and an increase in Tmax (the amount of 
time that a drug is present at the maximum concentration 
in serum) to approximately 3 hours. However, there is no 
clinically relevant effect on total absorption. Peak plasma 
  concentrations occur within 1.5 hours, with steady state 
achieved within 24–48 hours. Oral bioavailability exceeds 
90% and is independent of dose. Because pregabalin does 
not bind to plasma proteins, it is able to cross the blood-brain 
barrier, possibly through the involvement of the system L 
transporter for transport of large amino acids.28 Its apparent 
volume of distribution is approximately 0.5 L/kg.29
Pregabalin undergoes negligible metabolism, with 
approximately 90% of an administered dose recovered in the 
urine as unchanged pregabalin. The major urinary   metabolite, 
the N-demethylated derivative, accounts for only 0.9% of 
the dose. Pregabalin is not metabolized in the liver; it is 
eliminated primarily by renal excretion and has a mean 
elimination half-life of 6.3 hours in subjects with normal 
renal function.28 Mean renal clearance is nearly proportional 
to creatinine clearance and estimated at 67–80.9 mL/min in 
young healthy subjects. Pregabalin’s pharmacokinetic profile 
does not appear to be modified by race or gender.29
Because pregabalin undergoes negligible   metabolism in 
humans, does not bind to plasma proteins, and is   predominantly 
excreted unchanged in the urine, its   pharmacokinetics are 
unlikely to be affected by other agents through metabolic 
interactions or protein binding   displacement. Indeed, in vitro 
and in vivo studies have demonstrated that pregabalin is 
unlikely to be involved in significant pharmacokinetic drug 
interactions.29
Duloxetine and milnacipran
SNRIs are a class of antidepressants, whose mechanism of 
action is dual inhibition of serotonin and NE reuptake. The 
SNRIs duloxetine and milnacipran have been shown to inhibit 
5-HT and NE uptake in a dose-dependent manner in vitro 
and in vivo.30–36 SNRIs block 5-HT and NE transporters but, 
unlike TCAs, do not concomitantly block receptors for these 
neurotransmitters.37 Data from clinical and preclinical studies 
indicate that both drugs exert a more profound effect on NE 
reuptake than on 5-HT reuptake; the average selectivity for 
milnacipran and duloxetine (5-HT:NE) is 1:1.3 and 1:9.6, 
respectively.38 Duloxetine has also been shown to have a low 
affinity for the dopamine transporter, which may be clinically 
relevant at higher doses.38
Duloxetine
Duloxetine is well absorbed orally, with absorption 
beginning two hours after oral administration. Taking 
duloxetine with meals does not affect peak plasma concen-
tration. It does,   however, prolong the time to peak plasma 
  concentration by 6–12 hours and decreases the area under 
the   concentration-versus-time curve (AUC) by 10%. Eve-
ning versus morning administration of duloxetine results in Journal of Pain Research 2010:3 92
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Table 1 Examples of standard, new, and emerging therapeutic options for the treatment of fibromyalgia
Pharmacologic  
  treatment
Type Class Molecular  
mechanism(s)
APS 200522 EULAR 200723 Approval status
Standard  
treatments
NSAIDs (eg, aspirin, 
naproxen, ibuprofen)
N/A Selective or  
nonselective
COXb-1,2 inhibition;  
COXb-2 inhibition
NE NE Not approved
Opioids  
(eg, morphine,  
codeine, fentanyl,  
nalbuphine)
Scheduled or  
nonscheduled
Agonist,  
partial   agonist,  
agonist-  antagonist,  
or antagonist
Mu-, kappa-,  
delta-opioid  
receptor binding
NE NE Not approved
Tramadol Nonscheduled  
opioid analgesic;  
adjuvant analgesic  
(antidepressant)
Agonist; SNRI Mu-opioid  
  receptor binding;  
  norepinephrine/   
serotonin reuptake  
inhibition
ME SE Not approved
Amitriptyline Adjuvant analgesic  
(antidepressant)
TCA Na+ ion channel  
inhibition; NMDA  
receptor blockade  
(non-  neuroprotective)
SE SE Not approved
Fluoxetine Adjuvant analgesic  
(antidepressant)
SSRI Serotonin reuptake  
inhibition
ME SE Not approved
Gabapentin Adjuvant analgesic  
(anticonvulsant)
N/A VGCC alpha-2-delta  
subunit binding
N/A N/A Not approved
S-adenosylmethionine Adjuvant analgesic  
(antidepressant)
N/A Nervous system  
methylation
WE N/A Not approved
Cyclobenzaprine Skeletal muscle  
relaxant
N/A 5-HT2 receptor  
antagonist
SE N/A Not approved
Growth hormone N/A Hormone Numerous WE N/A Not approved
New treatments
Pregabalin Adjuvant analgesic  
(anticonvulsant)
N/A VGCC alpha-2-delta  
subunit binding
ME SE FDA-approved 
(2007)





ME SE FDA-approved 
(2008)









Pramipexole Adjuvant analgesic Agonist Selective non-ergoline  
D2, D3, and  
D4 dopamine  
receptor binding
N/A SE Not approved
Dextromethorphan Adjuvant analgesic Antagonist NMDAR N/A N/A Not approved
Ketamine Adjuvant analgesic Antagonist NMDAR N/A N/A Not approved
Sodium oxybate Adjuvant analgesic Central nervous  
system depressant
GABAB and GHB  
receptors (proposed)
N/A N/A Not approved
Low-dose naltrexone Opiate analgesia 
enhancer
Opioid antagonist Disruption of  
mu-opioid receptor  
Gs coupling via  
filamin A binding
N/A N/A Not approved
Delta-9-THC Adjuvant analgesic Psychoactive  
  cannabinoid
Numerous N/A N/A Not approved
Abbreviations: APS,   American Pain Society; COX, cyclooxygenase; EULAR, European League Against Rheumatism; FDA, Food and Drug Administration; FM, fibromyalgia; ME, 
modest efficacy; NA, not applicable; NE, no evidence of efficacy; NMDAR, N-methyl D-aspartate receptor; NSAID, nonsteroidal anti-inflammatory drug; SE, strong efficacy; SNRI, 
serotonin/  norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; VGCC, voltage-gated calcium ion channel; WE, weak 
efficacy.Journal of Pain Research 2010:3 93
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a three-hour delay in absorption and an approximately 33% 
increase in clearance.39 The plasma and elimination half-lives 
of duloxetine are approximately 12 hours.40 However, because 
duloxetine is able to cross the blood–brain barrier, its plasma 
half-life in the central nervous system (CNS) may be longer 
than in the peripheral measures typically reported.
Duloxetine is metabolized rapidly upon absorp-
tion. Lantz et al41 analyzed the effects of 20 mg duloxetine in 
healthy human subjects and found that the drug itself accounted 
for only 3% of the AUC and 9% of Cmax. Although duloxetine is 
metabolized extensively in the liver by the hepatic   cytochrome 
P450 (CYP) enzymes 1A2 and 2D6, none of its metabolites 
appear to be pharmacologically active.42 These metabolites, 
of which at least 25 have been identified, account for 70% of 
the duloxetine dose and are primarily excreted into the urine 
in the conjugated form. Twenty percent of the original dose 
is excreted in the feces.41 Duloxetine is highly protein bound 
(90%), primarily to albumin or 1-acid-glycoprotein,43 and 
its estimated volume of distribution is 1640 L.39,44
Because both CYP1A2 and CYP2D6 are responsible for 
duloxetine metabolism, it is not surprising that drugs that 
inhibit these molecules have a profound effect on duloxetine 
metabolism and concentration. Concomitant use of   duloxetine 
(40 mg once daily [QD]) with paroxetine (20 mg QD) 
increased the concentration of duloxetine AUC by about 60%, 
and greater degrees of inhibition are expected with higher 
doses of paroxetine. Similar effects would be expected with 
other potent CYP2D6 inhibitors (eg,   fluoxetine,   quinidine). 
In addition, concomitant   administration of 40 mg   duloxetine 
twice daily (BID) with 100 mg fluvoxamine, a potent CYP1A2 
inhibitor, to CYP2D6 poor metabolizer subjects (n = 14) 
resulted in a 6-fold increase in duloxetine AUC and Cmax. 
Co-administration of duloxetine with CYP1A2 and CYP2D6 
inhibitors should, therefore, be avoided.39
Milnacipran
Unlike typical TCAs, milnacipran is devoid of action at a large 
array of receptors, including alpha-1-, alpha-2-, beta-adrenergic, 
serotonergic (5HT-1A, 5HT-2A),   dopaminergic, muscarinic, 
histaminergic H-1, or   benzodiazepine receptors. While 
it does not inhibit rat brain monoamine oxidase A or B, 
it does appear to be a noncompetitive N-methyl D-aspartate 
  receptor (NMDAR) antagonist.45 It is currently unclear which 
  pharmacokinetic action(s) mediate milnacipran’s   therapeutic 
effects in FM, but a recent clinical study of female FM patients 
has provided insights as to the drug’s possible site of action. 
Gracely et al46 used functional   magnetic resonance imaging 
(fMRI) to identify areas of the brain exhibiting increased 
activity following administration of 100 mg milnacipran 
BID. In response to milnacipran   administration, patients’ 
brains showed an increase in activity in the thalamus,   caudate 
nucleus, cingulum, anterior insula, and amygdala, while 
patients who received placebo exhibited increased brain 
activity in only a parietal region and mid insula. The caudate 
nucleus, anterior insula, and amygdala are implicated in 
the descending pain modulation   inhibitory network,47 and 
increased posterior cingulum activity has been reported after 
treatment in chronic pain patients.48 These brain regions also 
function in reward-processing and emotional evaluation which 
are cognitive functions known to be involved in the experience 
of chronic pain, including that associated with FM.49–51 Taken 
together, these observations suggest a physiologic mechanism 
of action for milnacipran in FM patients involving both pain 
inhibitory networks and higher order cognitive functions 
(reward processing and emotional evaluation).
Absorption of milnacipran occurs rapidly after oral 
  administration, with plasma concentrations peaking 
  approximately two hours after an oral dose of 50 mg 
(Cmax = 120 ng/mL). Administering milnacipran with food 
does not change its bioavailability of ∼85%.39 QD or BID 
administration of 50–200 mg milnacipran produces a   linear 
increase in plasma concentrations; steady-state plasma levels 
are reached within several days.42,52 Milnacipran is   metabolized 
primarily by glucuronic acid conjugation, and its metabolites 
are not pharmacologically active at clinically relevant doses.53 
Milnacipran is not metabolized by CYP isoenzymes (P450 
2D6, P450 2C19, P450 3A4, and P450 1A2), nor does it 
modify the activity of the CYP isoenzymes. This   characteristic 
minimizes the risk of pharmacokinetic interaction when 
milnacipran is co-administered with other drugs.54 The mean 
elimination half-life of milnacipran is approximately eight 
hours, with the majority of the   original dose (90%) eliminated 
renally.39 Milnacipran’s plasma protein binding is low (13%) 
and nonsaturable and, like duloxetine, its metabolites are not 
pharmacologically active at clinical levels.42
The full pharmacokinetic profiles for pregabalin, 
  duloxetine, and milnacipran are available in the US 
  Prescribing Information for each drug.29,39,55
Efficacy
Pregabalin
Four randomized, double-blind, placebo-controlled trials have 
examined the efficacy of pregabalin monotherapy in the treat-
ment of FM.26,56–58 These studies have illustrated   pregabalin’s Journal of Pain Research 2010:3 94
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ability to improve the pain, fatigue, and sleep difficulties 
associated with FM, as well as patient health-related quality 
of life.7 Short-term trials ranged from 8–14 weeks,26,56,58 and 
a long-term durability study assessed pregabalin’s effects on 
FM over a 6-month period.57   Pregabalin was well tolerated 
overall, with no new adverse events occurring in FM patients 
that had not been reported with its use in other indications.24 
All three studies enrolled male and female patients 18 years 
of age who fulfilled the American College of Rheumatology 
(ACR) 1990 criteria for FM.59 Patients presented with a mean 
score of 4 on a 0–10 pain numeric rating scale and a score 
of 40 mm on the 100 mm visual analog scale (VAS) of the 
Short-Form McGill Pain Questionnaire (SF-MPQ).24
Several measures were used to assess pregabalin’s effects 
in the short-term studies, including FM intensity, sleep 
  quality diary, Medical Outcomes Study (MOS)-sleep mea-
sure,   Multidimensional Assessment of Fatigue (MAF), SF-36, 
and Hospital Anxiety and Depression Scale (HADS). Patients 
enrolled in the 8-week study were also asked to respond to 
Patient Global Impression of Change (PGIC) and Clinical 
Global Impression of change (CGIC) measures. Change in 
mean pain score from baseline was the primary endpoint in 
all three short-term studies. PGIC and   Fibromyalgia Impact 
Questionnaire (FIQ) were also assessed in the 14-week study 
if the primary endpoint was positive.
Pregabalin was administered 3 times per day (TID) during 
the 8-week study.26 Patients received equal doses of pregaba-
lin (150, 300, 450 mg/day), with all other   medications discon-
tinued 7 days prior to the study. Individuals previously found 
to be resistant to gabapentin treatment were excluded from 
this trial. Only the 450 mg/day pregabalin dose significantly 
reduced the pain score (-0.93 on a 0–10 scale; P  0.001) 
and increased the responder-rate versus placebo (29%, versus 
13% in the placebo group; P = 0.003). In a weekly analysis of 
pain scores,   significant improvement was seen through weeks 
1–7 but not at week 8. This result may be attributable to a 
combination of reduced statistical power, comparison with 
a group likely to contain many placebo responders, a lack 
of durability of analgesic effect, or symptom fluctuation.24 
Both the 300 and 450 mg/day doses of pregabalin signifi-
cantly improved sleep quality, fatigue, and global measures 
of change. Lack of change in the HADS score throughout the 
study suggests that reductions in pain scores are independent 
of   improvements in anxiety or depression.
The 13-week trial58 examined the effect of pregabalin on 
FM pain and symptom management. During this study, 748 
FM patients were randomly assigned to receive   pregabalin 
(300, 450, 600 mg/day BID) or placebo for 13 weeks. The 
primary outcome variable for the symptomatic relief of 
pain associated with FM was comparison of endpoint mean 
pain scores between each pregabalin group and   placebo. 
  Endpoint mean scores, PGIC, and FIQ total score were used 
as secondary outcome variables to assess the   management 
of FM. Patients in all pregabalin groups showed   statistically 
  significant improvement in endpoint mean pain score and 
in PGIC response compared with placebo (P = 0.0449: 
300 mg/day, -0.43; P = 0.0449: 450 mg/day, -0.47; 
P = 0.0070: 600 mg/day, -0.66).
Pregabalin was administered BID in escalating doses of 
300, 450, and 600 mg/day during the 14-week study.56 There 
was a 1-week baseline/placebo run-in   evaluation phase   during 
which patients who demonstrated a 30% decrease on the 
VAS were discontinued. This   evaluation period was followed 
by the primary 2-week dose-escalation phase. The primary 
outcome variable was comparison of   endpoint mean pain 
scores between each of the pregabalin groups and the placebo 
group. All three doses produced a   significant decrease in 
pain from weeks 1–14, with the   exception of the 300 mg/day 
dose at week 11. Mean changes in pain scores at the end 
point in pregabalin treated patients were significantly greater 
than in the placebo group (P  0.001: 300 mg/day, -0.71; 
450 mg/day -0.98; 600 mg/day, -1.00). Doses of 450 and 
600 mg/day   produced a significant (∼20%) improvement in 
FIQ total score   compared with placebo. All three doses of 
pregabalin were associated with significant improvement 
in sleep.
Pregabalin was administered BID during the 6-month 
durability study.57 The 6-month double-blind phase was 
preceded by a 1-week baseline phase, and followed by a 
6-week open-label phase to determine optimal dosage (300, 
450, 600 mg/day) and detect “responders” (those with 50% 
reduction in pain VAS score from open-label baseline and a 
rating of “much improved” on the PGIC). Primary outcome 
was time to loss of therapeutic response (LTR), defined 
as 30% reduction in pain (from open-label   baseline) or 
  worsening of FM in the opinion of the   investigator.   Secondary 
measures included the time to LTR for PGIC, CGIC, MOS 
(sleep), MAF, FIQ, and SF-36. The study enrolled a total 
of 1,051 patients, of which 663 completed the open-label 
study phase and 566 were subsequently randomized to the 
double-blind phase (287 to placebo, 279 to pregabalin). Pre-
gabalin (300–600 mg/day) significantly delayed the time to 
LTR approximately 5-fold versus placebo (7 versus 34 days, 
P  0.0001). All secondary measures were statistically 
superior to placebo as well, with substantial delays in time 
to LTR for sleep and fatigue. Thus, in those who respond, Journal of Pain Research 2010:3 95
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pregabalin demonstrates durability of effect for relieving the 
pain and accompanying symptoms of FM.
While the studies described here have perhaps been the 
most influential in determining FDA guidelines for the use of 
pregabalin in FM patients, a number of smaller   monotherapy 
or adjuvant therapy studies have also   demonstrated the 
  efficacy of pregabalin in FM treatment.60,61 It has been 
  suggested that the exclusion of gabapentin-resistant FM 
patients from the 8-week study increased the likelihood of 
a positive result.24 Taken together, however, the clinical trials 
conducted to date have demonstrated the short- and long-
term effectiveness of pregabalin for the treatment of FM pain. 
Pain reduction was most robust at doses of 300–600 mg/day, 
with onset of effect occurring within the first week of 
treatment. The recommended dose of   pregabalin in FM is 
300–450 mg/day BID.29 Doses of 600 mg/day produce an 
increase in adverse events with little additional benefit for 
pain relief. Doses that provide no significant reduction in 
FM pain often improve accompanying symptoms of the 
condition (eg, fatigue, sleep difficulties). Although a clinical 
  application of this finding has not yet been demonstrated, 
one could speculate on its utility in FM patients for which 
pain is not the primary concern.
Duloxetine
Five randomized, double-blind, placebo-controlled trials have 
assessed the efficacy of duloxetine in the treatment of FM to 
date.62–66 The two short-term studies62,63 assessed the efficacy 
and safety of duloxetine in FM patients over a 12-week 
period. The first trial62 enrolled a total of 207 male and female 
subjects, 38% of whom had concurrent MDD. Patients were 
recruited from 5 academic centers and 13 “independent 
research centers” within the US. Subjects were randomly 
assigned to receive duloxetine (60 mg/day BID) or placebo 
after a 1-week single-blind placebo treatment. FIQ total score 
and FIQ pain score were the co-primary outcome   measures. 
Compared with those who received   placebo, patients who 
received duloxetine showed a   significant improvement on the 
FIQ total score (P = 0.027), but not on the FIQ pain score 
(P = 0.130). Although   duloxetine decreased the pain and 
symptom   severity of FM in most patients,   improvements were 
significant in females only. These   findings were independent 
of baseline status of MDD.
The second 12-week study63 examined the effect of 
  duloxetine (60 mg/day QD or 60 mg/day BID) versus   placebo 
in 354 female FM patients with or without concurrent MDD. 
The primary outcome was the Brief Pain Inventory (BPI) 
average pain severity score, with response to treatment 
defined as 30% reduction in this score. Patients in both 
duloxetine groups had significantly greater improvement in 
BPI pain severity and interference scores, FIQ,   Clinical Global 
Impression of Severity (CGIS), Patient Global Impression 
of Improvement (PGII), and several quality of life measures 
compared with patients who received   placebo. The treatment 
effect of duloxetine on pain reduction was   independent of the 
effect on mood and the presence of MDD.
The remaining 3 trials64–66 assessed the long-term efficacy 
and safety of duloxetine for FM. Chappell et al65 conducted 
a Phase III, randomized, double-blind, placebo-controlled, 
parallel-group study of the effect of duloxetine (60 mg/day 
QD) on the pain and additional symptoms of FM versus 
placebo over a 6-month period. Patients randomly assigned 
to the 60 mg/day group were blindly escalated to 120 mg/
day if they did not exhibit a 50% reduction in the BPI-
Modified Short Form average pain score at week 13. Patients 
were allowed to increase their dose to 120 mg/day any time 
between weeks 13 and 23 if they exhibited 50% reduction 
in their BPI average pain score. Duloxetine 60/120 mg/day 
failed to demonstrate significant improvement over placebo 
on the co-primary outcome measures of BPI average pain 
severity from baseline to endpoint (P = 0.053) and the PGII 
at endpoint (P = 0.073). However, duloxetine did demon-
strate significant improvement compared with   placebo on 
several secondary outcome measures, including the FIQ pain 
item, Multidimensional Fatigue Inventory, CGIS, and Beck 
Depression Inventory-II total scores.
In the second 6-month trial,64 520 patients with or with-
out concurrent MDD were assigned to duloxetine (20, 60, 
120 mg/day QD) or placebo; the duloxetine 20 mg/day group 
was titrated to 60 mg/day after 3 months. The BPI average 
pain severity score and the PGII score served as co-pri-
mary outcome measures. Patients treated with duloxetine 
60 mg/day or 120 mg/day improved significantly more on the 
co-primary outcome measures at 3 months compared with 
those treated with placebo. Patients treated with 120 mg/day 
also demonstrated significant improvement at 6 months (BPI 
score, P = 0.003; PGII score, P = 0.012). Duloxetine was 
efficacious at doses of 60 or 120 mg/day in FM patients both 
with and without concurrent MDD.
The most recent trial of duloxetine in FM patients 
reports results from the 6-month extension phases of 
the   previously conducted studies (total treatment of 
12 months).64,65 Over half of the patients from the initial 
studies entered and   completed this extension phase (Study 
1,65 56%; Study 2,64 69%). Most treatment groups showed 
small mean change improvements in the BPI average pain Journal of Pain Research 2010:3 96
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severity score at the end of the 12-month period, supporting 
a positive risk/benefit profile for duloxetine in the long-term 
treatment of FM.
The trials completed on the use of duloxetine for FM 
differ with respect to dosing regimens, treatment   duration, 
and primary measures of pain. Not surprisingly, their 
results were inconsistent on measures of pain efficacy and 
  functional outcomes. Arnold et al67 conducted a pooled 
analysis of the first 4 of these studies (2 short-term62,63 
and 2 long-term64,65) to gain a better understanding of 
the efficacy of duloxetine after approximately 3 months’ 
treatment in FM patients. A total of 1,411 patients were 
randomly assigned to treatment across the 4 studies. 
  Seventy-nine patients were excluded from the pooled 
analysis because they had received a suboptimal dose 
(20 mg/day) of   duloxetine   during the   original trial. The 
remaining 1,332 patients received 60–120 mg/day dulox-
etine (797) or   placebo (535). The majority of the patients 
were middle-aged (mean = 50 years), female (95%), and 
white (88%), and 26% had a current   diagnosis of MDD. 
  Duloxetine produced a   significant improvement in BPI 
24-hour   average pain   severity compared with placebo (all 
assessments P  0.001). These results were observed dur-
ing the entire 3-month analysis period. Duloxetine-treated 
patients experienced a   significantly greater reduction in the 
total impact of FM symptoms and improvement in mood, 
  quality of life, and function than patients who received 
  placebo. Improvement on each of the eight SF-36 health 
domains and both of the   component summaries was sig-
nificant in the duloxetine-treated group compared with 
the placebo-treated group. No significant treatment-by-
subgroup interaction for mean changes in the BPI 24-hour 
average pain scores were found for the subgroup analyses 
of sex, race, and age. By combining the data from several 
studies, the investigators were able to gain statistical power 
by effectively analyzing data from a single large study. This 
statistical improvement facilitated a more accurate analysis 
of secondary functional results and efficacy outcomes in 
underrepresented patient subgroups.
The target and maximum duloxetine dose recommended 
for the treatment of FM is 60 mg/day QD, as this appears 
to provide the best long-term combination of clinical 
results and tolerability.39,42 A starting dosage of 30 mg/day 
is   recommended if patient tolerance is a concern. Because 
the clinical trials conducted to date have reported no 
  significant treatment-by-subgroup interactions, specific dose 
  recommendations based on sex, smoking status, age, and 
ethnicity are not warranted.68
Milnacipran
Two open-label studies have assessed the efficacy of 
  milnacipran in FM to date. Nagaoka et al69 conducted a 
12-week, uncontrolled, open-label study of milnacipran 
administration in 20 Japanese patients with FM and 
  concurrent depression. Doses of 30–100 mg/day were used, 
with a mean dosage of 59.7 mg/day and a modal dose of 
50 mg/day (13/18 completers). Using the Zung-Self-rating 
Depression Scale (Zung-SDS) to assess depressive   symptoms 
and a visual analog scale to measure pain (pVAS) and global 
condition (gVAS), the group found that milnacipran improved 
both pain and global condition at 8 weeks and depression at 
4 weeks. Importantly, only patients who were not depressed 
(Zung-SDS scores  50) at the end of the study exhibited 
significant improvements in pVAS (at 4, 8, and 12 weeks) 
and gVAS (at 8 and 12 weeks).
The second open-label study was a case report 
of a 35-year-old female with FM and concomitant 
temporomandibular disorder (TMD).70 The patient responded 
positively to milnacipran treatment and experienced a 
decrease in pVAS (100 to 40), Zung-SDS (70 to 32), and 
pain palpation score (32 to 17) over a 6-month period. Her 
only medications were ethyl loflazepate (2 mg/day) and mil-
nacipran (doses escalated from 30 to 120 mg/day over the 
6-month trial period). This finding may have considerable 
implications for FM treatment if replicated by larger studies, 
as FM and TMD often occur comorbidly.71
A Phase II, 12-week, randomized, double-blind, 
placebo-controlled, parallel-group, multicenter trial of 
  milnacipran in FM was conducted in the US in 2004.72 The 
study assessed pain scores in FM patients (n = 125) assigned 
to target doses of milnacipran (200 mg/day QD or BID). 
Pain was measured by the 2-week average daily pain score 
collected from electronic diary (e-diary) reports. Although 
several methods of clinical pain assessment were employed, 
including the Short Form McGill Pain Questionnaire, the 
Gracely and Kwilosz scale, and VAS, the primary outcome 
was a comparison of the e-diary reports from the final   
2 weeks of the trial with the 2-week baseline period. Comor-
bid depression was assessed by the Mini International Neu-
ropsychiatric Interview.
The majority of patients in both the QD and BID 
  milnacipran groups (81% and 92%, respectively) reached 
their target doses of 200 mg/day, compared with 95% in the 
placebo group. Reductions in reported pain reached   statistical 
significance for 9 of the 13 pain measures collected in the 
BID milnacipran group, but the QD group showed no sig-
nificant improvements. E-diary results from non-depressed Journal of Pain Research 2010:3 97
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patients taking milnacipran versus placebo (37% versus 
5%, P  0.012) were significantly better than those from 
depressed patients taking milnacipran versus placebo (38% 
versus 33%). This observation seems to   contradict the   findings 
of Nagaoka et al69 which suggest that milnacipran exhibits 
increased efficacy for reducing FM pain in depressed versus 
non-depressed patients. However, the observed   difference in 
effect between depressed and non-depressed patients in this 
Phase II trial was attributed to a higher placebo response in 
depressed patients rather than a greater efficacy of milnacip-
ran in non-depressed patients.
Four Phase III controlled studies have assessed the 
  efficacy of milnacipran in FM to date. The first two, 
  conducted in the US, were double-blind, parallel-group, 
placebo-controlled trials examining the effects of 100 or 
200 mg/day of   milnacipran in FM patients over a 3–6 month 
period.73,74 In the first study,73 1,196 patients with FM were 
randomized to a 3-month trial of milnacipran 100 mg/day 
(n = 399), 200 mg/day (n = 396), or placebo (n = 401). The 
smaller study, published in 2009, randomized 888 FM patients 
to similar groups to examine the effect of   milnacipran on 
FM and the pain of FM over a 6-month period. The primary 
efficacy measure in both studies was a composite responder 
  analysis. Pain   composite responders were defined as 
  individuals who achieved a reduction in pain of 30% or more 
compared with baseline as measured by VAS and recorded 
daily in an e-diary, and who rated   themselves as “very much 
improved” or “much improved” on the PGIC. FM   composite 
responders also had to   demonstrate at least a six-point 
improvement in their Short-Form 36 Health Survey (SF-36) 
physical   component   summary score. Significant improve-
ments in pain were   apparent from the first week in both stud-
ies. Statistically significant   differences between milnacipran 
and placebo were also seen on the condition as a whole, with 
relatively little evidence of a dose-related effect.52
The third Phase III study was conducted in Europe as 
a multicenter, multinational, double-blind, randomized, 
placebo-controlled trial.75 The 884 patients enrolled in the 
study were divided into two groups of approximately equal 
size and given either placebo or 200 mg/day milnacipran for 
12 weeks. The composite responder analysis method was also 
used to assess the effects of milnacipran on the pain of FM 
in this study, and the FIQ total score change from baseline 
was used as a secondary endpoint. Significant improvements 
in pain, sleep, and fatigue were apparent from weeks 1, 2, 
and 3, respectively.52 At the end of the 12-week 200 mg/day 
fixed dose period, milnacipran demonstrated a significantly 
greater improvement relative to placebo in both the primary 
and secondary criteria. FIQ results indicated a -3 difference 
in favor of milnacipran (P = 0.015). Several other measures, 
including the SF-36, FIQ physical function subscore, Mul-
tidimensional Fatigue Inventory total score, and Multiple 
Ability Self-Report Questionnaire cognition total score 
confirmed an overall improvement in the patient’s condition 
and functioning.
The final Phase III study examined the durability of 
response to milnacipran in a multicenter, randomized, blinded 
extension study from a 6-month, lead-in trial.76 The 449 FM 
patients enrolled in the study were either maintained on 
milnacipran 200 mg/day (n = 209) or re-randomized from 
placebo or 100 mg/day milnacipran at a 1:4 ratio to either 
  milnacipran 100 mg/day (n = 48) or 200 mg/day (n = 192) 
for an additional 6 months of treatment. Patients initially 
assigned to placebo and re-randomized to milnacipran 
200 mg/day experienced significant reductions in total pain, 
PGIC, stiffness, fatigue, and depressed mood. While the 
results from the 100 mg/day dose group showed a trend 
toward significance (P = 0.056), the number of patients in 
this group was likely too small to produce robust results.52
Clinical trials have demonstrated the efficacy of 
  milnacipran for both the short- and long-term treatment of FM. 
Studies addressing the effect of milnacipran on the   condition 
as a whole in addition to assessing changes in associated pain 
have revealed that many of the hallmark symptoms of FM (eg, 
fatigue, cognitive dysfunction, poor sleep) also improve with 
milnacipran treatment. The   recommended dose of   milnacipran 
for the treatment of FM is 100–200 mg/day BID.55 Dos-
ing should begin at 12.5 mg/day and gradually increase to 
100 mg/day over a 1-week period. Up to 200 mg/day may be 
administered based on individual patient response.
Safety and tolerability
Pregabalin
Most FM patients (∼84%) reported treatment-emergent 
adverse events during the pregabalin efficacy and safety 
studies. These events led to premature discontinuation from 
the studies in ∼16% of pregabalin patients (150–600 mg/day) 
and ∼9% of patients treated with placebo. These rates are 
similar to the adverse event discontinuation rates seen in the 
whole of the pre-marketing program for all indications (14% 
for pregabalin versus 7% for placebo).29
The majority of adverse events in the pregabalin FM 
studies were mild to moderate in nature. Dizziness and 
  somnolence were the most common adverse events, although 
the long-term 6-month study demonstrated that both adverse 
event rates and adverse event discontinuations decline with Journal of Pain Research 2010:3 98
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time. Pregabalin treatment produced no   clinically   significant 
  findings in analyses of hematology, blood chemistry, 
  urinalysis, visual function, physical or neurologic signs, 
  urinalysis or electrocardiograms.24 While results suggest 
that the occurrence of adverse events is dose-dependent, 
  differences are not always statistically significant.7
In vitro and in vivo studies have shown that pregabalin is 
unlikely to be involved in significant pharmacokinetic drug 
interactions. Importantly, no pharmacokinetic   interactions 
were seen during the coadministration of pregabalin with 
oxycodone, lorazepam, or ethanol. Additive effects on 
cognitive and gross motor functioning were observed, 
  however, suggesting the need for dose reduction of either 
or both concomitant drugs. Because pregabalin is eliminated 
primarily by renal excretion, dose reduction is necessary in 
renal dysfunction with the need for creatinine clearance to 
be monitored.29
Duloxetine
SNRIs, such as duloxetine and milnacipran, appear to have 
greater efficacy, greater likelihood of producing remission, 
and greater improvement of painful physical symptoms than 
the SSRIs widely used in FM treatment. However, SNRIs 
are also   associated with a greater incidence of side effects. 
Duloxetine’s side effects are generally somewhat dose-related 
at the beginning of treatment, and most diminish after the 
first few days.42 Clinical trials to date have demonstrated 
that   duloxetine is safe and well tolerated in the dosage range 
of 20 to 120 mg/day for up to 1 year.66 Nausea, dry mouth, 
  hyperhidrosis, dizziness, headache, insomnia, constipation, 
and fatigue were reported most frequently, leading to a 
  premature discontinuation rate of ∼21%. The rates for nausea 
with duloxetine appear to be comparable with those found 
with other SSRIs and SNRIs. For those patients for whom 
tolerance is a concern, starting at a loser dosage (30 mg/day) 
lowers the likelihood and severity of nausea. Detke et al77 
found no significant blood pressure differences in patients 
taking duloxetine (60 mg/day) for major depression compared 
with patients who received placebo. However, a small but 
statistically significant increase in heart rate was observed. 
Longer term monitoring is recommended, particularly for 
patients with hypertension or cardiac anomalies. The rate 
of duloxetine-related insomnia in FM patients may be of 
concern (10.4% with duloxetine treatment versus 5.6% 
with placebo treatment),64 as sleep dysfunction is a major 
associated symptom with FM. The occurrence of insomnia 
is likely to be lessened by taking the drug in the morning.42 
It is generally recommended that duloxetine be taken with 
food, as this prolongs the time to peak plasma concentration 
and can limit the development of side effects.78
The FDA recently determined that a “black box” warning 
would be required for all antidepressants. Although there 
are no data indicating that duloxetine is causally related to 
suicidality,42 caution and close observation should be used 
in patients taking duloxetine, particularly during the initial 
weeks of treatment. Adequate treatment of underlying 
depression is essential for minimizing suicide risk.
Duloxetine is metabolized by CYP1A2 and CYP2D6 
enzymes and moderately inhibits the latter. Thus, the   clinician 
should consider decreasing the dosage of   concomitant 
drugs that are metabolized by CYP2D6, such as TCAs 
(eg,   nortriptyline, amitriptyline, imipramine);   phenothiazines; 
and Type 1C antiarrhythmics (eg,   propafenone, flecainide). 
Of clinical relevance, duloxetine does not inhibit or induce the 
CYP3A4 system, but administration of CYP1A2   inhibitors 
may result in elevated duloxetine   concentrations.42 The 
CYP1A2 inhibitor thioridazine should not be   coadministered 
with duloxetine due to the risk of serious ventricular 
arrhythmias and sudden death potentially associated with 
elevated plasma levels of thioridazine.39 Adverse effects on 
the fetus have been found in animal reproductive studies, 
rendering duloxetine a Category C agent for women who 
are pregnant.42
Because it is metabolized extensively by the liver, 
  duloxetine should not ordinarily be prescribed to patients with 
substantial alcohol use or evidence of chronic liver disease, 
and clinicians should assess and monitor alcohol use and 
caution against concomitant excessive alcohol use.   Smoking 
is suspected to result in a 30% reduction of   duloxetine 
from expected serum concentrations through its effects on 
CYP1A2. However, it is unclear whether this alteration in 
drug metabolism is clinically significant enough to warrant 
a dose adjustment.39 Because renal clearance approximates 
70% for both the parent drug and its metabolites, duloxetine 
is not recommended in patients with severe renal disease or 
those requiring dialysis.42
Milnacipran
Milnacipran (100, 200 mg/day) has been shown to be 
well tolerated up to 1 year.76 As an SNRI, milnacipran 
exhibited the anticipated adverse event profile of nausea, 
headache, tachycardia, and hypertension typical of this 
class.   Sinusitis, constipation, hyperhidrosis, and dizziness 
were also reported in 5% of patients. Although these 
events led to a   premature discontinuation rate of ∼18%, 
most (90%) were mild to moderate in nature. The most Journal of Pain Research 2010:3 99
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frequent adverse event,   nausea, decreased with time, and 
milnacipran’s effects on blood pressure and heart rate were 
rarely of clinical   significance (0.2%–1.1%).52 No clinically 
relevant changes were seen in hematology, urinalysis, or 
other clinical laboratory   parameters, with the exception 
of one study79 that reported mild elevations in alanine 
transferase in 7% of milnacipran patients (compared with 
4% on placebo).
Milnacipran exhibits low and nonsaturable plasma 
protein binding.42 The liver CYP system is not involved 
in its   metabolism, making dosage adjustments for 
patients with liver impairment unnecessary.80 The limited 
  reciprocal   pharmacokinetic interaction between milnacipran 
and CYP isoenzymes allows the drug to be coadministered 
with   antidepressants.81 However, both milnacipran and 
  duloxetine should be considered to have potentially seri-
ous   interactions if given concomitantly with monoamine 
oxidase   inhibitors. Depending on the dosages, both could 
induce adverse   serotonergic interactions if given over 
a prolonged period with SSRIs, and possibly even with 
herbals such as St. John’s Wort.42 No pharmacokinetic 
changes were seen with   coadministration of milnacipran 
and   lorazepam, lithium,   carbamazepine, or levomeproma-
zine.   Milnacipran’s   pharmacokinetics are not altered by 
  alcohol,52 and   milnacipran is not expected to cause clini-
cally significant P450   inhibition or induction.81 However, 
the   pharmacokinetics of milnacipran are markedly affected 
by renal impairment. Puozzo et al82 found the elimination 
half-life of severely impaired subjects to be approximately 
three times that of the control group.
Similar to TCAs, repeated administration of   milnacipran 
decreases the responsiveness of serotonergic 5-HT-2A   receptors, 
increases the responsiveness of the alpha-1-adrenergic system, 
and induces adaptive changes in the dopaminergic system, 
particularly by enhancing the functional responsiveness of 
dopamine D2 and D3   receptors.54,83 These findings may be 
extrapolated to include other SNRIs, although their clinical 
significance has not yet been determined.
The side effects and adverse events associated with 
  milnacipran and duloxetine may be explained in part by 
their inhibition of 5-HT and NE uptake.42 The overall 
sensory sensitivity seen in FM may predispose patients to 
a higher incidence of adverse events compared with other 
patient populations. Peak drug levels have been suggested 
to be a significant factor in the generation of certain side 
effects.52 BID administration (as opposed to QD) is thus 
recommended in order to increase milnacipran’s tolerability 
in FM patients.84
Patients
Adherence to prescription medications is critical for their 
effectiveness, and such adherence has historically been 
  problematic in the management of FM. Sewitch et al85 
found the rate of nonadherence in a cohort of 127 female 
FM patients to be 47.2%, although it is unknown whether 
this was due to lack of efficacy, side effects, cost, or 
  psychosocial   factors. Dobkin et al86 reported that patient-
physician   agreement on the patient’s well-being and a 
lower level of patient distress predicted greater adherence 
to general FM treatment. Better adherence to medication 
was also seen in patients experiencing greater pain and 
better emotional health. Clinicians should instruct patients 
about the brief time courses of many common drug-related 
side effects in order to diminish adverse event-related 
nonadherence.42
In contrast with earlier prescription medications used for 
the treatment of FM, pregabalin, duloxetine, and milnacipran 
may increase adherence because of their favorable efficacy, 
safety, and tolerability profiles. Many of the side effects and 
discontinuations seen in the clinical trials of these drugs 
can be avoided in clinical practice by employing flexible 
  dosing regimens that consider the overall sensory   sensitivity 
  characteristic of FM patients. The relative success of such 
regimens in FM treatment has precipitated the adage “start 
low, go slow.” Practitioners also often prescribe a higher 
  proportion of the daily dose of pregabalin at bedtime rather 
than equally splitting BID doses. In some cases only a 
night time dose is given, similar to the dosing of tricyclics 
in chronic pain states.87 In addition, the recommended 
BID administration of pregabalin may improve patient 
  compliance compared with the TID dosing of gabapentin, 
a similar alpha-2-delta ligand widely used in the treatment 
of FM.88 Physician assistants can prove particularly valuable 
to the large percentage of FM patients who need to adjust 
their medications several times before finding a suitable 
combination and dosing schedule, as these clinicians can 
often provide adequate time and education to patients at a 
reasonable cost.89
Even with the development of new, safer and more 
efficacious drugs, current pharmacologic treatment for FM 
remains largely empiric, creating enormous   challenges for 
primary care physicians. Despite positive results from   clinical 
trials, many FM patients find that even new   prescription 
medications do not sufficiently control their symptoms and/or 
are difficult to tolerate in a clinical setting. As a result, the 
majority of FM patients obtain only   modest relief from drug 
treatments and in general   compliance is low.90Journal of Pain Research 2010:3 100
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In 2005, an internet survey of 2,596 FM patients revealed 
that, as expected, newer medications such as duloxetine 
and pregabalin were being used by only a small percentage 
of respondents (8%).7 This percentage has undoubtedly 
increased over the last few years. While clinical trials suggest 
an increased propensity for patient preference, satisfaction, 
adherence, and compliance through more favorable efficacy, 
safety, and tolerability profiles, the actual long-term clinical 
favorability of pregabalin, duloxetine, and milnacipran for 
the treatment of FM remains to be determined.
Conclusions
FM is a complex, multidimensional, chronic pain condition 
of heterogeneous nature. The goals of FM treatment are to 
  alleviate pain, increase restorative sleep, and improve   physical 
function through a reduction in associated   symptoms.7 The 
identification and treatment of all pain sources that may be 
present in addition to FM, such as peripheral inflammatory 
or neuropathic pain generators (eg, comorbid osteoarthritis 
or neuropathic pathologies) or visceral pain (eg, comorbid 
irritable bowel syndrome) is central to the proper clinical 
management of FM.15
Overall, depression and anxiety are among the most 
  common comorbidities with FM, with prevalence rates   ranging 
in studies from 20%–80% and 13%–63.8%,   respectively.91 
Unfortunately, clinical trials conducted to date report little 
or no improvement in FM-associated psychiatric symptoms 
after administration of pregabalin, duloxetine, or   milnacipran. 
However, FM-associated pain scores often improved   during 
trials of all three drugs, regardless of the presence of 
  concurrent anxiety or depression. This suggests that the pain, 
anxiety, and depression that frequently occur comorbidly 
with FM do not share the same underlying mechanism. The 
apparent lack of efficacy of pregabalin and milnacipran for 
the treatment of FM-associated anxiety and depression may be 
explained by the methodologic design of the relevant   clinical 
trials – all of the studies excluded patients with   concurrent 
MDD, limiting the ability for improvement in depressive 
symptoms. It is interesting to note that all of the studies of 
duloxetine, a drug approved by the FDA for the treatment of 
MDD and generalized anxiety disorder, included patients 
with MDD and still did not achieve significant results. Further 
studies are warranted to adequately address the effects of these 
drugs on FM-associated depression and anxiety.
It is increasingly evident that adequate treatment of FM 
presents a significant clinical challenge. High   prevalence, 
frequent comorbidities, a constellation of different and fluc-
tuating symptoms, and frustration with current   treatment 
modalities has resulted in the use of a variety of   different 
  pharmacotherapies, alone or in combination.92 New 
  pharmacologic approaches, including pregabalin, duloxetine, 
and milnacipran, have demonstrated improved safety and 
efficacy in clinical trials. A recent study by Vera-Llonch et al 
suggests that treatment of FM with pregabalin is likely to be 
associated with substantially reduced use of other pain-related 
medications and cost savings based on US drug costs 
(0.46–0.97 US$).93 Similar reductions in medication use and 
healthcare costs are expected for duloxetine and   milnacipran, 
given their performance in clinical trials to date.
The mechanisms of action of pregabalin, duloxetine, 
and milnacipran are thought to be related to proposed 
  pathophysiologies of FM. However, these new therapeutic 
agents are still not effective for all FM patients. Recent work 
by Katz et al suggests that the diagnostic criteria for FM 
may be partially responsible, as there is currently no gold 
standard for FM diagnosis.94 While the ACR criteria for 
FM are the de facto criteria used for research, they are not 
generally utilized by non-rheumatologists. Rheumatologists 
may also diagnose FM in patients who do not satisfy the 
ACR criteria. These findings raise the question of whether 
clinical trials of FM treatments based on ACR criteria (ie, all 
of the studies described in this article) actually represent 
the population of FM patients seen by rheumatologists in 
clinical practice.
Regardless of the cause, the overall clinical   ineffectiveness 
of single-drug treatment approaches in FM suggests the 
need for combined pharmacologic approaches that target 
multiple biochemical abnormalities and are developed on a 
somewhat individual basis. Emerging therapies, including 
NMDAR antagonists, dopamine agonists, sodium oxybate, 
low-dose naltrexone, and delta-9-THC have proven   effective 
in preliminary studies, and may play important roles in 
combination treatment approaches. However, a thorough 
discussion of these emerging therapies is beyond the scope 
of this review.
In summary, pregabalin, duloxetine, and milnacipran 
appear safe and effective for the treatment of FM, although 
additional trials are warranted for efficacy, remission, 
  indications, safety, and tolerability. The clinical trials 
  conducted to date employed a variety of assessment tools and 
primary outcome measures, making the results difficult to 
cross-compare. Pharmacologic fMRI is a robust and   reliable 
method for detecting central effects of pain-relieving drugs 
that will likely play a fundamental role in assessing the   efficacy 
of current and future FM therapies. This technique may also 
be used as a guide for optimizing the potentially diverse Journal of Pain Research 2010:3 101
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therapeutic requirements of this patient group.7 If future data 
support emerging patterns, it is likely that these drugs will 
provide valuable options for the treatment of FM.
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